Madrigal Pharmaceuticals experienced a significant surge in stock value after the FDA authorized its groundbreaking treatment for fatty liver disease. The medication, resmetirom (Rezdiffra), was approved for noncirrhotic non-alcoholic steatohepatitis (NASH), a prevalent and severe fatty liver disease. The analysts at Jefferies estimate a peak sales potential of $3.4 billion in the U.S. and European Union. The biotech company's shares soared by over 250% in 2022 following positive trial results for the drug.